By Colin Kellaher
MacroGenics on Wednesday said its co-founder and longtime leader, Scott Koenig, is leaving the biopharmaceutical company.
The Rockville, Md., company said Koenig plans to step down as president and chief executive early next year, and that its board has hired Heidrick & Struggles to lead the search for a new CEO.
MacroGenics said it has signed a separation agreement with Koenig effective at the end of February that includes continued payment of his annual salary and target bonus for two years.
Koenig, who helped found MacroGenics in 2000 and has been president, CEO and a board member since September 2001, received a salary of nearly $705,000 and total compensation of more than $3.7 million in 2023.
MacroGenics on Wednesday said Koenig has agreed to resign from the board and will serve as an adviser through February 2030 in exchange for the continued vesting of any unvested stock-option and restricted stock unit awards.
The company said its board has formed a special committee to oversee the executive transition process.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 30, 2024 09:50 ET (13:50 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。